ACM-001 COVID-19 vaccine

Artificial Cell Membranes (ACM) containing recombinant SARS-CoV-2 (beta-variant) spike protein and ACMs containing CpG adjuvant

Also Known As:

ACM-001; ACM-001 vaccine; ACM-SARS-CoV-2-beta ACM-CpG

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Neoplasms (Cancer) 05/01/2023 - "The small molecule ACM-001 improves cardiac function in a rat model of severe cancer cachexia." 05/01/2023 - "Here, we investigated the effects of ACM-001 (0.3 or 3 mg/kg/day) in comparison to carvedilol (3 or 30 mg/kg/day), metropolol (50 or 100 mg/kg/day), nebivolol (1 or 10 mg/kg/day) and tertatolol (0.5 or 5 mg/kg/day) on cardiac mass and function in a rat cancer cachexia model. "
2.	Cachexia 05/01/2023 - "The small molecule ACM-001 improves cardiac function in a rat model of severe cancer cachexia." 05/01/2023 - "Here, we investigated the effects of ACM-001 (0.3 or 3 mg/kg/day) in comparison to carvedilol (3 or 30 mg/kg/day), metropolol (50 or 100 mg/kg/day), nebivolol (1 or 10 mg/kg/day) and tertatolol (0.5 or 5 mg/kg/day) on cardiac mass and function in a rat cancer cachexia model. "
3.	Body Weight (Weight, Body) 05/01/2023 - "ACM-001 reduced body weight loss (placebo: -34 ± 2.4 g vs. 3 mg/kg/day ACM-001: -14.8 ± 8.4 g, p = 0.033). "